AstraZeneca Plc reported another quarter of growth in the three months to 31 March, continuing a trend that started more than a year ago with the launch of new medicines for cancer and diabetes. It now has nine products with annual sales of $1 billion or more. During the quarter, sales increased across every geographical region and therapy area, especially for oncology. Group revenue reached $6.4 billion for an increase of 16% at actual exchange rates, and 17% at constant rates. This included product sales of $6.3 billion and collaboration revenue of $43 million.
